Skip to content
rugpijnwatnu.nl

Treatments.
What works and what doesn't.

Last updated Sources checked

How this page was written

An overview of 16 treatments for back pain, rated on how strong the independent evidence is and sorted from strongest to weakest. From exercise therapy to surgery: not everything that is offered actually works.

First, what does “works” mean?

In 2025 a review pooled 301 placebo-controlled trials covering 56 non-surgical treatments for back pain. The result is sobering: roughly one in ten works better than a placebo, and those that do produce small effects (Cashin et al., BMJ Evidence-Based Medicine 2025). For acute back pain only NSAIDs came out ahead. For chronic back pain: exercise, spinal manipulation, taping, antidepressants and capsaicin-type agents.

That does not make the rest useless. A treatment can be worth doing because it is safe, keeps you moving, or is what a guideline advises, even when the pain-relieving effect is hard to prove. But it does mean you should be suspicious of anyone promising a lot. On this page, a high score means the evidence is strong, not that the effect is large.

Why guidelines disagree
Good evidence that it helpsLimited or conflicting evidenceDoes not work, or advised against

Category

Movement & therapy

Movement is the foundation of treatment.

Exercise therapy

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Recommended (WHO, conditionally; NICE; KNGF)

A structured exercise programme is what the guidelines put first: the WHO (2023), NICE (2016) and KNGF (2021) all recommend it, the WHO conditionally. For back pain that has lasted a long time, it is one of the few treatments that beats a placebo, though the difference is small (Cashin et al., 2025).

More information

Physiotherapy

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Added value not demonstrated (Zorginstituut); recommended by its own professional body (KNGF)

Exercise therapy, manual therapy and pain education combined, directly accessible without a referral. WHO and NICE recommend exercise; the recommendation of physiotherapy as such comes mainly from the professional body of physiotherapists. The Dutch Zorginstituut, which represents no profession, reviewed 42 studies in 2024 and concluded the added value over no physiotherapy is not sufficiently demonstrated (standpunt 2024).

More information

Manual therapy and chiropractic

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Only within a package (NICE)

For chronic back pain, spinal manipulation is one of the few treatments that beats a placebo, though by a small margin (Cashin et al., 2025). For recent back pain it added nothing over ordinary care in a 1,000-person trial (PACBACK, JAMA 2026).

More information

Massage

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Only within a package (NICE), conditional (WHO)

Temporary pain relief at best; a lasting effect on pain and function has not been shown, and the evidence is weak (Cochrane 2015). NICE lists massage as part of manual therapy, only within a package that includes exercise; the WHO recommends it conditionally.

Acupuncture

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

NICE: do not offer, WHO: conditional

Better than no treatment, but barely better than sham acupuncture, which suggests most of the effect is context (Cochrane 2020). NICE advises against it and Dutch GP literature calls the effect mainly placebo (Huisarts & Wetenschap); the WHO recommends it conditionally.

More information

Category

Medication

Sometimes useful as temporary support, never the solution itself.

NSAIDs

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Recommended short-term (WHO, NICE)

A small effect for acute back pain (Cochrane 2020), and for acute pain the only medicine that beats a placebo (Cashin et al., 2025). Use as briefly as possible, at the lowest effective dose. Stomach protection if you have risk factors; not with kidney disease or heart failure without asking your doctor (NHG).

More information

Paracetamol (acetaminophen)

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

NICE advises against, the Dutch GP starts with it

The PACE trial (Lancet 2014) showed paracetamol is no better than placebo for acute low back pain. A Cochrane review confirms this (Cochrane 2016). NICE advises against paracetamol on its own; the WHO guideline on chronic back pain makes no recommendation. Your Dutch GP usually still starts here, because it has the fewest side effects (NHG standard on pain).

More information

Opioids

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Not recommended (WHO 2023)

OPAL trial (Lancet 2023): no better than placebo for acute back pain, more side effects. High risk of dependence. The WHO (chronic back pain) and NICE advise against opioids as routine care; NICE allows a weak opioid for acute pain only when an NSAID is not possible or does not work.

More information

Category

Mind & behaviour

Pain is never 'just in your head', but your brain does play a part. These approaches can help.

Cognitive behavioural therapy (CBT)

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Recommended, conditionally (WHO, NICE chronic pain)

Addresses negative thought patterns and fear-avoidance, and is one of the few treatments with demonstrated benefit one to two years later, though the effect is small (Jenkins et al., Lancet Rheumatol 2025).

More information

Multidisciplinary rehabilitation

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

WHO: conditional; NICE withdrew in 2026

Combination of physiotherapy, psychology and medical guidance, meant for chronic back pain with psychosocial factors. The benefits on pain and function are small (Cochrane 2014). In 2026 NICE withdrew its recommendation, and the Zorginstituut narrowed what basic insurance covers (standpunt 2026).

More information

Cognitive Functional Therapy (CFT)

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Promising, one large trial (RESTORE)

Integrates pain education, graded exposure and lifestyle modification. RESTORE trial (Lancet 2023): greater reduction in pain and daily-life limitations than usual care in chronic back pain, still present at 12 months. No guideline mentions CFT yet, and the evidence rests mainly on this one trial.

More information

Category

Injections & surgery

Only useful in specific situations. Be critical.

Surgery (emergency)

No score: there is no alternative
How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Necessary for cauda equina (clinical consensus)

Surgery is necessary and urgent for cauda equina syndrome: decompression within about 48 hours gives a better chance of recovering bladder function and muscle strength than later surgery (Ahn et al., 2000). That evidence is observational, because surgery cannot be tested against no surgery; hence no score. Increasing weakness in your leg from a herniated disc can also be a reason for surgery: don't wait, call your GP straight away (NHG).

More information

Herniated disc surgery

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Consider after 10-12 weeks (NL guideline)

About 75% recovers within three months without surgery (LRS guideline). A discectomy relieves faster, but after one to two years the result is comparable (Peul et al., NEJM 2007). For sciatica lasting 4 to 12 months surgery does come out clearly better (Bailey et al., NEJM 2020).

More information

Epidural injection (radiating pain)

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Consider for severe sciatica (NICE)

For severe pain radiating into the leg an epidural corticosteroid injection can be considered when pain medication falls short (NL guideline LRS). The effect is real but small and short-lived: about 5 points less leg pain on a scale of 0 to 100 (Cochrane 2020).

More information

Facet joint injections

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Advised against (NICE)

The Dutch MINT trials (JAMA 2017) found no clinically relevant benefit of radiofrequency denervation on top of an exercise programme. NICE advises against facet joint injections for low back pain. An SI joint injection scores slightly higher (2 out of 5): NICE does use it as a diagnostic test. Since 1 January 2016 radiofrequency denervation for chronic non-specific low back pain is no longer part of Dutch basic insurance (Zorginstituut).

More information

Surgery (non-specific back pain)

How do we rate this?

We look at whether the pain decreases and whether people can move and function better again, not at how satisfied patients were with the treatment, because that says little about whether it really works. Independent reviews and bodies such as Cochrane, the WHO, NICE and the Zorginstituut weigh most. When a profession recommends its own treatment, that alone does not earn a high score. Strong comparative research is scarce for back pain, so some ratings are based on limited evidence.

Advised against (NICE)

There is no good evidence that surgery helps non-specific back pain. Spinal fusion did no better than intensive rehabilitation (Brox et al., Spine 2003), with more risk of complications. NICE advises against fusion outside research and against disc replacement.

More information

Next step